Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema randomized clinical trial

Paul Mitchell, Neil M Bressler, Keith Tolley, Meghan Gallagher, Jennifer Petrillo, Alberto Ferreira, Francesco Bandello

Research output: Contribution to journalArticle

Abstract

Importance Few data are available on relative changes in vision-related function after treatment for diabetic macular edema (DME). Objective To determine the impact of intravitreal ranibizumab, 0.5 mg, compared with laser on patient-reported visual function. DESIGN Phase 3, randomized, double-masked, 12-month study. Setting Outpatient retina practices in Australia, Canada, and Europe. PARTICIPANTS Patients 18 years or older with type 1 or 2 diabetes mellitus and visual impairment due to DME. Interventions Patients were randomized to ranibizumab plus sham laser (n = 116), ranibizumab plus laser (n = 118), or sham injections plus laser (n = 111). Ranibizumab and sham injections were given for 3 consecutive months then as needed; laser plus sham laser treatment was given at baseline then as needed. Main Outcomes And Measures National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) scores at0, 3, and 12 months for patients receiving 1 or more study treatments with 1 ormorepostbaselineNEIVFQ- 25assessmentsandlastobservationcarriedforwardformissingdata. Results Mean baseline NEI VFQ-25 composite scores were 72.8, 73.5, and 74.1 in the ranibizumab, laser, and ranibizumab plus laser groups, respectively. At 12 months, the mean composite scores (95%CIs) improved by 5.0 (ranibizumab vs laser, 2.6 to 7.4; P =.01 vs laser) and 5.4 (ranibizumab plus laser vs laser alone, 3.3 to 7.4; P =.004 vs laser) from baseline in the ranibizumab and ranibizumab plus laser groups, respectively, compared with 0.6 (-1.8 to 3.0) for the laser group. Near activities scores improved by 9.0 (ranibizumab vs laser, 5.0 to 13.0; P =.01) and 9.1 (ranibizumab plus laser vs laser, 5.6 to 12.6; P =.006) compared with 1.1 (-3.0 to 5.2) for the laser group, whereas distance activities scores improved by 5.3 (ranibizumab vs laser, 1.8 to 8.9; P =.04) and 5.6 (ranibizumab plus laser vs laser, 2.3 to 9.0; P =.03) compared with 0.4 (-3.1 to 3.8) for the laser group. Patients with better baseline visual acuity or lower central retinal thickness had greater improvements with ranibizumab treatment compared with laser in composite and some subscale scores compared with patients with worse visual acuity or higher central retinal thickness. CONCLUSIONS AND RELEVANCE These data provide vision-related, patient-reported outcome evidence that mirrors visual acuity outcomes and supports benefits from ranibizumab or ranibizumab plus laser treatment for patients with DME and characteristics similar to those enrolled in this randomized clinical trial.

Original languageEnglish (US)
Pages (from-to)1339-1347
Number of pages9
JournalJAMA Ophthalmology
Volume131
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Macular Edema
Lasers
Randomized Controlled Trials
Therapeutics
Ranibizumab
National Eye Institute (U.S.)
Visual Acuity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema randomized clinical trial. / Mitchell, Paul; Bressler, Neil M; Tolley, Keith; Gallagher, Meghan; Petrillo, Jennifer; Ferreira, Alberto; Bandello, Francesco.

In: JAMA Ophthalmology, Vol. 131, No. 10, 10.2013, p. 1339-1347.

Research output: Contribution to journalArticle

Mitchell, Paul ; Bressler, Neil M ; Tolley, Keith ; Gallagher, Meghan ; Petrillo, Jennifer ; Ferreira, Alberto ; Bandello, Francesco. / Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema randomized clinical trial. In: JAMA Ophthalmology. 2013 ; Vol. 131, No. 10. pp. 1339-1347.
@article{cf3d90ea94ee4c53b510a77284e16619,
title = "Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema randomized clinical trial",
abstract = "Importance Few data are available on relative changes in vision-related function after treatment for diabetic macular edema (DME). Objective To determine the impact of intravitreal ranibizumab, 0.5 mg, compared with laser on patient-reported visual function. DESIGN Phase 3, randomized, double-masked, 12-month study. Setting Outpatient retina practices in Australia, Canada, and Europe. PARTICIPANTS Patients 18 years or older with type 1 or 2 diabetes mellitus and visual impairment due to DME. Interventions Patients were randomized to ranibizumab plus sham laser (n = 116), ranibizumab plus laser (n = 118), or sham injections plus laser (n = 111). Ranibizumab and sham injections were given for 3 consecutive months then as needed; laser plus sham laser treatment was given at baseline then as needed. Main Outcomes And Measures National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) scores at0, 3, and 12 months for patients receiving 1 or more study treatments with 1 ormorepostbaselineNEIVFQ- 25assessmentsandlastobservationcarriedforwardformissingdata. Results Mean baseline NEI VFQ-25 composite scores were 72.8, 73.5, and 74.1 in the ranibizumab, laser, and ranibizumab plus laser groups, respectively. At 12 months, the mean composite scores (95{\%}CIs) improved by 5.0 (ranibizumab vs laser, 2.6 to 7.4; P =.01 vs laser) and 5.4 (ranibizumab plus laser vs laser alone, 3.3 to 7.4; P =.004 vs laser) from baseline in the ranibizumab and ranibizumab plus laser groups, respectively, compared with 0.6 (-1.8 to 3.0) for the laser group. Near activities scores improved by 9.0 (ranibizumab vs laser, 5.0 to 13.0; P =.01) and 9.1 (ranibizumab plus laser vs laser, 5.6 to 12.6; P =.006) compared with 1.1 (-3.0 to 5.2) for the laser group, whereas distance activities scores improved by 5.3 (ranibizumab vs laser, 1.8 to 8.9; P =.04) and 5.6 (ranibizumab plus laser vs laser, 2.3 to 9.0; P =.03) compared with 0.4 (-3.1 to 3.8) for the laser group. Patients with better baseline visual acuity or lower central retinal thickness had greater improvements with ranibizumab treatment compared with laser in composite and some subscale scores compared with patients with worse visual acuity or higher central retinal thickness. CONCLUSIONS AND RELEVANCE These data provide vision-related, patient-reported outcome evidence that mirrors visual acuity outcomes and supports benefits from ranibizumab or ranibizumab plus laser treatment for patients with DME and characteristics similar to those enrolled in this randomized clinical trial.",
author = "Paul Mitchell and Bressler, {Neil M} and Keith Tolley and Meghan Gallagher and Jennifer Petrillo and Alberto Ferreira and Francesco Bandello",
year = "2013",
month = "10",
doi = "10.1001/jamaophthalmol.2013.4592",
language = "English (US)",
volume = "131",
pages = "1339--1347",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema randomized clinical trial

AU - Mitchell, Paul

AU - Bressler, Neil M

AU - Tolley, Keith

AU - Gallagher, Meghan

AU - Petrillo, Jennifer

AU - Ferreira, Alberto

AU - Bandello, Francesco

PY - 2013/10

Y1 - 2013/10

N2 - Importance Few data are available on relative changes in vision-related function after treatment for diabetic macular edema (DME). Objective To determine the impact of intravitreal ranibizumab, 0.5 mg, compared with laser on patient-reported visual function. DESIGN Phase 3, randomized, double-masked, 12-month study. Setting Outpatient retina practices in Australia, Canada, and Europe. PARTICIPANTS Patients 18 years or older with type 1 or 2 diabetes mellitus and visual impairment due to DME. Interventions Patients were randomized to ranibizumab plus sham laser (n = 116), ranibizumab plus laser (n = 118), or sham injections plus laser (n = 111). Ranibizumab and sham injections were given for 3 consecutive months then as needed; laser plus sham laser treatment was given at baseline then as needed. Main Outcomes And Measures National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) scores at0, 3, and 12 months for patients receiving 1 or more study treatments with 1 ormorepostbaselineNEIVFQ- 25assessmentsandlastobservationcarriedforwardformissingdata. Results Mean baseline NEI VFQ-25 composite scores were 72.8, 73.5, and 74.1 in the ranibizumab, laser, and ranibizumab plus laser groups, respectively. At 12 months, the mean composite scores (95%CIs) improved by 5.0 (ranibizumab vs laser, 2.6 to 7.4; P =.01 vs laser) and 5.4 (ranibizumab plus laser vs laser alone, 3.3 to 7.4; P =.004 vs laser) from baseline in the ranibizumab and ranibizumab plus laser groups, respectively, compared with 0.6 (-1.8 to 3.0) for the laser group. Near activities scores improved by 9.0 (ranibizumab vs laser, 5.0 to 13.0; P =.01) and 9.1 (ranibizumab plus laser vs laser, 5.6 to 12.6; P =.006) compared with 1.1 (-3.0 to 5.2) for the laser group, whereas distance activities scores improved by 5.3 (ranibizumab vs laser, 1.8 to 8.9; P =.04) and 5.6 (ranibizumab plus laser vs laser, 2.3 to 9.0; P =.03) compared with 0.4 (-3.1 to 3.8) for the laser group. Patients with better baseline visual acuity or lower central retinal thickness had greater improvements with ranibizumab treatment compared with laser in composite and some subscale scores compared with patients with worse visual acuity or higher central retinal thickness. CONCLUSIONS AND RELEVANCE These data provide vision-related, patient-reported outcome evidence that mirrors visual acuity outcomes and supports benefits from ranibizumab or ranibizumab plus laser treatment for patients with DME and characteristics similar to those enrolled in this randomized clinical trial.

AB - Importance Few data are available on relative changes in vision-related function after treatment for diabetic macular edema (DME). Objective To determine the impact of intravitreal ranibizumab, 0.5 mg, compared with laser on patient-reported visual function. DESIGN Phase 3, randomized, double-masked, 12-month study. Setting Outpatient retina practices in Australia, Canada, and Europe. PARTICIPANTS Patients 18 years or older with type 1 or 2 diabetes mellitus and visual impairment due to DME. Interventions Patients were randomized to ranibizumab plus sham laser (n = 116), ranibizumab plus laser (n = 118), or sham injections plus laser (n = 111). Ranibizumab and sham injections were given for 3 consecutive months then as needed; laser plus sham laser treatment was given at baseline then as needed. Main Outcomes And Measures National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) scores at0, 3, and 12 months for patients receiving 1 or more study treatments with 1 ormorepostbaselineNEIVFQ- 25assessmentsandlastobservationcarriedforwardformissingdata. Results Mean baseline NEI VFQ-25 composite scores were 72.8, 73.5, and 74.1 in the ranibizumab, laser, and ranibizumab plus laser groups, respectively. At 12 months, the mean composite scores (95%CIs) improved by 5.0 (ranibizumab vs laser, 2.6 to 7.4; P =.01 vs laser) and 5.4 (ranibizumab plus laser vs laser alone, 3.3 to 7.4; P =.004 vs laser) from baseline in the ranibizumab and ranibizumab plus laser groups, respectively, compared with 0.6 (-1.8 to 3.0) for the laser group. Near activities scores improved by 9.0 (ranibizumab vs laser, 5.0 to 13.0; P =.01) and 9.1 (ranibizumab plus laser vs laser, 5.6 to 12.6; P =.006) compared with 1.1 (-3.0 to 5.2) for the laser group, whereas distance activities scores improved by 5.3 (ranibizumab vs laser, 1.8 to 8.9; P =.04) and 5.6 (ranibizumab plus laser vs laser, 2.3 to 9.0; P =.03) compared with 0.4 (-3.1 to 3.8) for the laser group. Patients with better baseline visual acuity or lower central retinal thickness had greater improvements with ranibizumab treatment compared with laser in composite and some subscale scores compared with patients with worse visual acuity or higher central retinal thickness. CONCLUSIONS AND RELEVANCE These data provide vision-related, patient-reported outcome evidence that mirrors visual acuity outcomes and supports benefits from ranibizumab or ranibizumab plus laser treatment for patients with DME and characteristics similar to those enrolled in this randomized clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84885933408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885933408&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2013.4592

DO - 10.1001/jamaophthalmol.2013.4592

M3 - Article

C2 - 23974915

AN - SCOPUS:84885933408

VL - 131

SP - 1339

EP - 1347

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 10

ER -